A study of women's knowledge regarding human papillomavirus infection, cervical cancer and human papillomavirus vaccines

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 46, Issue 4, 2006, Pages 311-315

  Giles, Michelle ^a   Garland, Suzanne ^a  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

Cervical cancer; Human papillomavirus; Knowledge; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MEDICAL INFORMATION SYSTEM; PAPANICOLAOU TEST; PATIENT ATTITUDE; PATIENT EDUCATION; POPULATION DISTRIBUTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; SEXUALLY TRANSMITTED DISEASE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HEALTH EDUCATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUESTIONNAIRES; RISK FACTORS; SEXUAL BEHAVIOR; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VICTORIA;

EID: 33745610507     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2006.00598.x     Document Type: Article

References (10)

1. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997; 102: 3-8.
2. Ferlay J, Bray F, Pisani P. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0. Lyon: IARCPress, 2004.
3. Australian Institute of Health and Welfare (AIHW) 2005. Cervical screening in Australia 2002-03. AIHW Cat. No. 26. Canberra: Australian Institute of Health and Welfare (Cancer Series no. 31).
4. Australian Institute of Health and Welfare (AIHW) 2003. Cervical screening in Australia and 2000-01 and 1999-2000. AIHW Cat No. 19. Canberra: Australian Institute of Health and Welfare (Cancer Series no. 24).
5. Koutsky L, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651.
6. Harper DM, Franco EL, Wheeler CM et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection of human papillomavirus type 16 and 18 in young women: A randomised controlled trial. Lancet 2004; 364: 1757-1765.
7. Skjeldestad F for the FUTURE II Steering Committee; Department of Epidemiology, SINTEF Health Research, Trondheim, Norway. Prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. Abstract 43rd Annual Meeting of Infectious Diseases Society of America; October 2005, San Francisco, CA, USA.
8. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 2003; 88: 63-73.
9. Pitts M, Clarke T. Human papillomavirus infections and risks of cervical cancer: What do women know? Health Educ Res 2002; 17: 706-714.
10. Waller J, McCaffery K, Forrest S et al. Awareness of human papillomavirus among women attending a well woman clinic. Sex Transm Infect 2003; 79: 320-322.